In The News
-
Empirico Inks Drug Target Discovery Alliance With Antisense Drug Firm Ionis
GENOMEWEB—Empirico said on Thursday that it has formed a drug discovery alliance with antisense therapeutics firm Ionis Pharmaceuticals.
-
Empirico scores $660M deal with Ionis and lands a series A-2 fundraiser
BIOWORLD—It’s a big day for privately held Empirico Inc. as it embarks on a massive combo pharma deal with Ionis Pharmaceuticals Inc. while racking up a $12.5 million series A-2 financing.
-
Ionis finds new partner in a young biotech and its hopeful founder
ENDPOINTS NEWS—Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.
-
Empirico Raises $17M, Inks 3-Year Antisense Collaboration with Ionis
Xconomy San Diego —Empirico, a biotech that has developed tools to analyze genomics data and use those insights to identify potential therapeutic targets, has signed a collaboration deal with antisense drug developer Ionis Pharmaceuticals that includes a $10 million equity investment.
-
Deals with Empirico and Aro to help Ionis bring new targets, tissues to early-stage pipeline
BIOCENTURY—Ionis is turning to two young biotechs to build off the success of its antisense oligonucleotides and expand the reach of its platform. The company announced a pair of deals with Empirico and Aro on Thursday, designed to bring antisense therapeutics into new tissues and indications.